Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline.

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to ...

Structure Therapeutics (NASDAQ:GPCR) shared new top-line results from its ACCESS II clinical program for aleniglipron, an ...

Novo Nordisk NVO and Structure Therapeutics GPCR have emerged as noteworthy companies in the obesity space. A market leader ...

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Structure Therapeutics (GPCR) is drawing attention as its ...

Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. U.S. equity markets ...

Structure Therapeutics Inc. ADR advanced stock charts by Barron's. View GPCR historical stock data and compare to other stocks, and exchanges.

Pfizer is one of several drugmakers working to develop an alternative to injectable weight loss drugs. Still, it’s far behind rivals like Eli Lilly and Novo Nordisk, who already lead the market with ...

Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong ...

Structure Therapeutics (GPCR) stock jumped 10% after its GLP-1 pill aleniglipron posted 16.3% weight loss, outperforming Lilly and Novo's oral candidates.